Biotechnology Swedish immuno-oncology firm Alligator Bioscience saw its shares jump more than 13% to 0.26 kronor this morning, as it announced the positive outcome of regulatory interactions with the Paul Ehrlich Institute (PEI) of Germany and the US Food and Drug Administration (FDA) regarding the CMC development of mitazalimab, which is in development as a first-line treatment for metastatic pancreatic cancer in combination with mFOLFIRINOX. 16 January 2025